This article was reviewed by Craig Primack, MD, FACP, FAAP, FOMA. Wegovy (semaglutide) is approved by the U.S. Food and Drug Administration (FDA) for weight loss and weight management in people with ...

India has taken a big step forward in obesity treatment with the launch of the much-talked-about weight-loss drug Wegovy by Danish drugmaker Novo Nordisk. After getting approval from the US Food and ...

Imagine this scenario: You’ve been diligently working toward your weight management goals, and your healthcare team has prescribed Wegovy (semaglutide). You’re excited, you’ve done your research, and ...

PLAINSBORO, N.J., Aug. 15, 2025 /PRNewswire/ -- Novo Nordisk (NVO) today announced that the US Food and Drug Administration (FDA) has approved a new indication for Wegovy ® (semaglutide) injection 2.4 ...

Zepbound (tirzepatide) and Wegovy (semaglutide) are prescription drugs used for weight loss and weight management. Both drugs come as a liquid solution for injection under the skin. Zepbound and ...

Wegovy (semaglutide) is a once-weekly injection that was first approved in 2017 to help with weight loss and lower the risk of heart problems. Now, the FDA has approved it to treat a liver condition ...

A "game changer" weight loss injection used by celebrities including Twitter boss Elon Musk is to be made available through the NHS amid warnings that the drug is not a "quick fix". In a "pivotal ...

Aug 7 (Reuters) - Eli Lilly (LLY.N), opens new tab said on Thursday that its experimental GLP-1 pill helped patients lose 12.4% of their body weight after 72 weeks in a late-stage study, less than ...

Novo Nordisk’s oral semaglutide 25 mg achieved up to 16.6% weight loss in a landmark study, rivaling injectable Wegovy. The pill also improved cardiovascular risk factors and physical activity levels.

It’s official. Children in the UK as young as 12 are taking Wegovy to help them slim down – and it’s transforming their lives for the better. When I first read the headlines, I nearly spat my coffee ...

Investors wiped $70 billion off Novo Nordisk’s market value on Tuesday after the maker of weight-loss drug Wegovy issued a profit warning and named a new CEO, as it battles rising competition in the ...